Jack A. Khattar - Aug 6, 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
President, CEO, Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Aug 6, 2025
Transactions value $
-$2,270,135
Form type
4
Date filed
8/8/2025, 04:40 PM
Previous filing
Jun 23, 2025
Next filing
Aug 26, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Khattar Jack A. President, CEO, Director C/O SUPERNUS PHARMACEUTICALS INC., 9715 KEY WEST AVENUE, ROCKVILLE /s/ Timothy C. Dec, as attorney-in-fact 2025-08-08 0001539937

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $779K +60K +5.95% $12.98 1.07M Aug 6, 2025 Direct F1
transaction SUPN Common Stock Sale -$1.55M -38.5K -3.6% $40.24 1.03M Aug 6, 2025 Direct F2
transaction SUPN Common Stock Options Exercise $779K +60K +5.82% $12.98 1.09M Aug 6, 2025 Direct F1
transaction SUPN Common Stock Sale -$1.6M -38K -3.49% $42.00 1.05M Aug 6, 2025 Direct
transaction SUPN Common Stock Options Exercise $2.06M +81.3K +7.72% $25.30 1.13M Aug 6, 2025 Direct F1
transaction SUPN Common Stock Sale -$2.74M -63.5K -5.6% $43.12 1.07M Aug 6, 2025 Direct F3
holding SUPN Common Stock 1.01M Aug 6, 2025 By the KBT Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -60K -23.53% $0.00 195K Aug 6, 2025 Common Stock 60K $12.98 Direct F4
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -60K -30.77% $0.00 135K Aug 6, 2025 Common Stock 60K $12.98 Direct F4
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -81.3K -25% $0.00 244K Aug 6, 2025 Common Stock 81.3K $25.30 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.70. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.56. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F4 The option vested in four equal installments beginning on March 1, 2017.
F5 The option vests in four equal installments beginning on February 24, 2018